Clinical trials to study the efficacy of PPARα agonists in the treatment of mood, neurodevelopmental, and neurodegenerative disorders are emerging and promise to provide evidence to support novel pharmacological strategies for the therapeutic management of conditions that share a strong neuroinflammatory component, including major depression, PTSD, and ASD, but also PD and AD. The gene discussed is PPARA; the disease is Parkinson disease.